Wells Fargo & Company Lowers Disc Medicine (NASDAQ:IRON) Price Target to $78.00

Disc Medicine (NASDAQ:IRON) had its price target reduced by investment analysts at Wells Fargo & Company from $109.00 to $78.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 20.97% from the stock’s current price.

Other research analysts also recently issued research reports about the company. Morgan Stanley restated an “overweight” rating and issued a $120.00 price objective on shares of Disc Medicine in a research note on Thursday, January 8th. Stifel Nicolaus began coverage on Disc Medicine in a research note on Monday, November 3rd. They set a “buy” rating and a $125.00 price objective for the company. TD Cowen reaffirmed a “buy” rating on shares of Disc Medicine in a research note on Friday, December 19th. Truist Financial raised their price target on Disc Medicine from $86.00 to $114.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Wednesday, January 21st. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $104.82.

Disc Medicine Stock Down 1.7%

IRON stock opened at $64.48 on Tuesday. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $2.43 billion, a PE ratio of -12.05 and a beta of 0.88. The stock’s 50 day moving average is $77.84 and its 200-day moving average is $75.21. Disc Medicine has a twelve month low of $30.82 and a twelve month high of $99.50.

Insider Activity at Disc Medicine

In related news, CEO John D. Quisel sold 13,264 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $833,775.04. Following the sale, the chief executive officer owned 226,064 shares of the company’s stock, valued at $14,210,383.04. The trade was a 5.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Jonathan Yen-Wen Yu sold 3,231 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $203,100.66. Following the completion of the sale, the chief operating officer owned 54,324 shares in the company, valued at approximately $3,414,806.64. This trade represents a 5.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 273,605 shares of company stock valued at $24,193,736 over the last ninety days. Insiders own 3.64% of the company’s stock.

Institutional Trading of Disc Medicine

Hedge funds and other institutional investors have recently made changes to their positions in the stock. TimesSquare Capital Management LLC purchased a new position in Disc Medicine during the third quarter valued at $12,038,000. Y Intercept Hong Kong Ltd increased its holdings in shares of Disc Medicine by 361.4% during the third quarter. Y Intercept Hong Kong Ltd now owns 43,287 shares of the company’s stock valued at $2,860,000 after acquiring an additional 33,905 shares in the last quarter. Atle Fund Management AB raised its position in shares of Disc Medicine by 85.3% in the 3rd quarter. Atle Fund Management AB now owns 45,690 shares of the company’s stock worth $3,019,000 after purchasing an additional 21,038 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Disc Medicine by 11.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 843,616 shares of the company’s stock worth $44,678,000 after purchasing an additional 84,278 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in Disc Medicine during the 3rd quarter valued at about $689,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Key Disc Medicine News

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Disc will pursue a traditional U.S. approval pathway for bitopertin after the FDA declined the new fast‑track route — this gives management a concrete regulatory path forward rather than abandoning the program. Read More.
• Positive Sentiment: Cantor Fitzgerald initiated/maintained a positive stance and Stifel Nicolaus stuck with a buy rating, which can support institutional demand despite headline volatility. Read More.
• Neutral Sentiment: Management hosted an investor discussion/transcript addressing the FDA Complete Response Letter — investors are parsing details on requested data, resubmission timeline and implications for ongoing trials (APOLLO). The call reduces information asymmetry but does not yet remove regulatory risk. Read More.
• Neutral Sentiment: Analyst commentary is mixed: some emphasize lingering regulatory risk and timing, while others point to upside if APOLLO or other data are favorable — expect divergent price targets and trading around trial news. Read More.
• Negative Sentiment: Reports indicate the FDA rejection was coupled with skepticism from external advisers, increasing the likelihood of additional data requests or delay for approval — a material near‑term negative for valuation. Read More.
• Negative Sentiment: Multiple insiders — including the CEO and other senior officers — disclosed sales of shares on Feb 17 (and a pattern of recent sales by some insiders), which the market often interprets as a negative signal about near‑term outlook. Read More.
• Negative Sentiment: Pomerantz LLP launched an investor investigation into Disc Medicine, introducing potential litigation risk and added headline pressure that can weigh on the stock until resolved. Read More.
• Negative Sentiment: Several firms trimmed price targets today (even where ratings stayed positive), reflecting a lower near‑term valuation baseline until regulatory clarity is restored. That likely cements downward pressure on the stock in the short term. Read More.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.